查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026823

乳癌診斷市場預測至2034年－按產品類型、類別、應用、最終用戶和地區分類的全球分析

Breast Cancer Diagnostics Market Forecasts to 2034 - Global Analysis By Product, Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球乳癌診斷市場規模將達到 62.2 億美元，在預測期內以 9.4% 的複合年成長率成長，到 2034 年將達到 127.7 億美元。

乳癌診斷對於早期發現和製定有效的治療方案至關重要。早期發現能夠及時干預，提高存活率，並減少侵入性治療的需求。診斷有助於確定腫瘤類型，指南個人化治療，並監測治療效果。這使得醫療專業人員能夠根據每位患者的個別需求量身定做治療方案，從而最佳化治療效果。

根據美國癌症協會統計，2021 年僅在美國就診斷出約 281,550 例新的乳癌病例，預計相關死亡人數為 49,290 人。

乳癌發生率增加

乳癌發生率的激增是推動乳癌診斷市場發展的主要動力。隨著全球病例數的增加，對先進診斷技術和篩檢方法的需求也日益成長。早期發現對於有效治療至關重要，這推動了乳房X光檢查、分子診斷和切片檢查等診斷工具的創新。對準確、快速乳癌診斷需求的激增是推動市場擴張的關鍵因素。

過度診斷和假陽性的風險

過度診斷和假陽性是指檢測結果錯誤顯示有癌症，但實際上並沒有癌症。這會帶給患者不必要的精神痛苦、焦慮和恐懼。此外，它通常會導致進一步的侵入性檢查，例如切片檢查，這可能會使患者面臨身體傷害和不適。生活在對癌症的恐懼中的心理負擔，以及額外醫療檢查帶來的經濟負擔，都會影響病人的整體健康。

人工智慧（AI）與機器學習（ML）的融合

將人工智慧 (AI) 和機器學習 (ML) 應用於乳癌診斷，透過分析複雜的數據模式，顯著提升診斷的準確性和效率，從而支援早期檢測和個人化治療策略。 AI 和 ML 使醫療專業人員能夠做出更明智的決策，最終改善患者的治療效果。這項進步不僅將革新診斷能力，還將推動市場創新，並有望在應對全球最普遍、最嚴峻的健康挑戰之一方面，顯著提高診斷的準確性和有效性。

診斷程序高成本

乳癌診斷程序涉及乳房X光檢查、磁振造影和基因檢測等先進技術，這些技術在研發、維護和營運方面都需要大量投資。這些診斷工具的複雜性，加上嚴格的品質標準，導致檢測成本高昂。這種經濟障礙阻礙了早期發現和治療，對患者的預後產生了負面影響。因此，市場在實現診斷技術的廣泛應用、改善患者預後以及應對乳癌對公眾健康的廣泛影響方面面臨諸多挑戰。

新冠疫情的感染疾病

新冠疫情對市場產生了重大影響。常規檢查的延誤、患者就診次數的減少以及醫療資源的緊張導致乳癌診斷率下降。供應鍊和醫療服務的中斷也影響了市場成長。然而，公眾意識的提高以及遠端醫療和人工智慧診斷等技術的進步正在推動市場復甦，並重塑後疫情時代乳癌診斷的格局。

在預測期內，切片檢查部分預計將是最大的部分。

預計切片檢查部分將顯著成長。切片檢查是確定是否存在惡性腫瘤的關鍵步驟。它包括從受影響區域取一小塊組織樣本，並在顯微鏡下進行檢查。切片檢查結果有助於制定治療策略，並使醫療專業人員能夠為每位乳癌患者量身定做有效的治療方法和介入措施。早期準確的切片檢查結果對於確保及時、適當地治療乳癌至關重要。

預計在預測期內，熱成像產業將呈現最高的複合年成長率。

預計在預測期內，熱成像產業將呈現最高的複合年成長率。乳癌診斷中的熱成像技術利用紅外線影像來檢測乳房組織的熱模式和潛在異常。它是一種非侵入性、無輻射的技術，能夠可視化與血流和細胞活動相關的溫度變化。由於它是非接觸式的，無需壓迫，因此可以提供更舒適的檢查體驗，並且是傳統診斷工具的重要補充。

市佔率最大的地區：

預計在預測期內，亞太地區將佔據最大的市場佔有率，這主要得益於公眾意識的提高、醫療保健支出的成長以及診斷技術的進步。 GE醫療、雅培、西門子醫療和羅氏診斷等領導企業均位於該地區，提供廣泛的診斷技術。亞太地區患者數量的不斷成長以及政府為提高公眾對癌症的認知和篩檢而採取的舉措，預計將推動市場保持上升趨勢。

複合年成長率最高的地區：

預計北美地區在預測期內將呈現最高的複合年成長率。在北美市場中，美國佔最大的市場佔有率。眾多市場參與者都位於該地區，包括Bio-Rad Laboratories、Agendia、Genomic Health和Myread Genetics。這些領導企業正透過併購和合作等策略來擴大市場佔有率。乳癌是美洲許多國家最常見的癌症。乳癌發生率的上升，以及北美醫療基礎設施的發展，預計將推動整體市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球乳癌診斷市場：依產品分類

  • 基於設備的產品
  • 平台型產品

第6章 全球乳癌診斷市場：依類型分類

  • 切片檢查
    • 針刺切片
    • 手術切片檢查
  • 診斷影像
  • 驗血
    • 生物標記檢測
    • 循環性腫瘤細胞（CTC）檢測
  • 基因組檢測
    • 基因表現分析
    • 次世代定序（NGS）
  • 核醫學診斷
    • 前哨淋巴結活體組織切片
    • 正子斷層掃描（PET）
  • 組織病理學
  • 其他類型

第7章 全球乳癌診斷市場：依應用分類

  • 篩檢
    • 乳房X光檢查
    • 乳房自我檢測（BSE）
    • 臨床乳房檢查（CBE）
    • 分子乳房影像（MBI）
    • 乳腺超音波檢查
  • 診斷影像
    • X光
    • 磁振造影（MRI）
    • 電腦斷層掃描（CT）
    • 超音波
    • 分子成像技術
  • 熱成像
  • 其他用途

第8章 全球乳癌診斷市場：依最終用戶分類

  • 醫院和診所
  • 診斷中心和醫學檢測實驗室
  • 其他最終用戶

第9章 全球乳癌診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Hologic Inc
  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Abbott Laboratories
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • PerkinElmer Inc.
  • Agilent Technologies
  • Becton, Dickinson and Company（BD）
  • Myriad Genetics Inc.
  • Sysmex Corporation
  • NanoString Technologies
  • Genomic Health
  • Illumina Inc.
  • Bio-Rad Laboratories
  • Sienna Cancer Diagnostics
  • Cepheid
  • Invivo Corporation
  • Aurora Diagnostics
Product Code: SMRC24634

According to Stratistics MRC, the Global Breast Cancer Diagnostics Market is accounted for $6.22 billion in 2026 and is expected to reach $12.77 billion by 2034 growing at a CAGR of 9.4% during the forecast period. Breast cancer diagnostics are crucial for early detection and effective treatment planning. Early identification enables timely intervention, improving survival rates and reducing the need for aggressive treatments. Diagnostics aid in characterizing tumor types, guiding personalized therapies, and monitoring treatment response. They empower healthcare professionals to tailor interventions to individual patient needs, optimizing outcomes.

According to the American Cancer Society, it is estimated that approximately 281,550 new cases of breast cancer will be diagnosed in 2021, with an expected 49,290 related deaths in the U.S. alone.

Market Dynamics:

Driver:

Rising incidence of breast cancer

The escalating prevalence of breast cancer is a key catalyst for the breast cancer diagnostics. With a rising number of cases globally, there is an increasing demand for advanced diagnostic technologies and screening methods. Early detection is crucial for effective treatment, driving innovation in diagnostic tools such as mammography, molecular diagnostics, and biopsy. This surge in demand for accurate and timely breast cancer diagnosis is a significant factor fueling the expansion of the market.

Restraint:

Risk of overdiagnosis & false positives

Overdiagnosis and false positive result erroneously indicates the presence of cancer when it is not actually present. This can lead to unnecessary emotional distress, anxiety, and fear for the patient. Moreover, it often triggers further invasive procedures such as biopsies, exposing individuals to potential physical harm and discomfort. The psychological toll of living with the fear of cancer and the financial burden of additional medical tests can impact a patient's overall well-being.

Opportunity:

Integration of artificial intelligence & machine learning

The integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostics enhance the accuracy and efficiency of diagnostic processes by analyzing complex data patterns, aiding in early detection, and personalized treatment strategies. AI and ML empower healthcare professionals to make more informed decisions, leading to improved patient outcomes. This advancement not only revolutionizes diagnostic capabilities but also fosters innovation in the market, promising enhanced precision and effectiveness in addressing one of the most prevalent and critical health challenges worldwide.

Threat:

High cost of diagnostic procedures

Breast Cancer Diagnostics procedures involve advanced technologies such as mammography, MRI, and genetic testing, which incur high development, maintenance, and operational expenses. The intricate nature of these diagnostic tools, coupled with stringent quality standards, results in expensive procedures. This financial barrier limits timely detection and treatment, negatively impacting patient outcomes. As a result, the market faces challenges in achieving widespread adoption, improving patient outcomes, and addressing the broader public health impact of breast cancer.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the market. Delays in routine screenings, reduced patient visits, and strained healthcare resources have led to a decline in the diagnosis of breast cancer cases. Disruptions in supply chains and healthcare services have also affected the market's growth. However, increased awareness and technological advancements, such as telemedicine and AI-driven diagnostics, have driven recovery and reshaped the landscape for breast cancer diagnostics in the post-pandemic era.

The biopsy segment is expected to be the largest during the forecast period

The biopsy segment is estimated to have a lucrative growth. Biopsy is a crucial procedure for confirming malignancy. It involves extracting a small tissue sample from the affected area for examination under a microscope. Biopsy results guide treatment decisions, helping healthcare professionals tailor effective therapies and interventions for patients diagnosed with breast cancer. Early and accurate biopsy results are pivotal in ensuring timely and appropriate management of breast cancer.

The thermography segment is expected to have the highest CAGR during the forecast period

The thermography segment is anticipated to witness the highest CAGR growth during the forecast period. Thermography in breast cancer diagnostics involves using infrared imaging to detect heat patterns and potential abnormalities in breast tissue. It is a non-invasive and radiation-free technique that highlights variations in temperature associated with blood flow and cellular activity. Its non-contact nature and lack of compression contribute to a more comfortable experience, making it a valuable adjunct to traditional diagnostic tools.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the rising awareness, increased healthcare expenditure, and advancements in diagnostic technologies. It has the presence of top most players namely GE Healthcare, Abbott Laboratories, Siemens Healthineers and Roche Diagnostics. These companies often offer a diverse range of diagnostic technologies. The market is expected to continue its upward trajectory, driven by a growing patient population and government initiatives promoting cancer awareness and screening in the Asia-Pacific region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. The U.S. held the largest market share of the market in North America. The region is home to several market players including Bio-Rad Laboratories, Agendia, Genomic Health and Myriad Genetics. These key companies are adopting strategies such as mergers and acquisitions and partnerships, to acquire a larger market share. Breast cancer is the most commonly diagnosed cancer in most American countries. The rising prevalence of breast cancer, coupled with the development of healthcare infrastructure in North America, is expected to drive overall market growth.

Key players in the market

Some of the key players profiled in the Breast Cancer Diagnostics Market include Hologic Inc, GE Healthcare, Siemens Healthineers, Philips Healthcare, Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, PerkinElmer Inc., Agilent Technologies, Becton, Dickinson and Company (BD), Myriad Genetics Inc., Sysmex Corporation, NanoString Technologies, Genomic Health, Illumina Inc., Bio-Rad Laboratories, Sienna Cancer Diagnostics, Cepheid, Invivo Corporation and Aurora Diagnostics.

Key Developments:

In December 2023, GE HealthCare released a new, all-in-one platform of artificial intelligence (AI) apps to support clinicians with breast cancer detection and improved workflow productivity called MyBreastAI Suite.

In May 2023, Pfizer and Thermo Fisher Scientific Inc. have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.

Products Covered:

  • Instrument-based Products
  • Platform-based Products

Types Covered:

  • Biopsy
  • Imaging
  • Blood Tests
  • Genomic Tests
  • Nuclear Medicine Diagnostics
  • Histopathology
  • Other Types

Applications Covered:

  • Screening
  • Diagnostic Imaging
  • Thermography
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Centers & Medical Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Instrument-based Products
  • 5.3 Platform-based Products

6 Global Breast Cancer Diagnostics Market, By Type

  • 6.1 Introduction
  • 6.2 Biopsy
    • 6.2.1 Needle Biopsy
    • 6.2.2 Surgical Biopsy
  • 6.3 Imaging
  • 6.4 Blood Tests
    • 6.4.1 Biomarker Testing
    • 6.4.2 Circulating Tumor Cells (CTCs) Testing
  • 6.5 Genomic Tests
    • 6.5.1 Gene Expression Profiling
    • 6.5.2 Next-Generation Sequencing (NGS)
  • 6.6 Nuclear Medicine Diagnostics
    • 6.6.1 Sentinel Lymph Node Biopsy
    • 6.6.2 Positron Emission Tomography (PET)
  • 6.7 Histopathology
  • 6.8 Other Types

7 Global Breast Cancer Diagnostics Market, By Application

  • 7.1 Introduction
  • 7.2 Screening
    • 7.2.1 Mammography
    • 7.2.2 Breast Self-Examination (BSE)
    • 7.2.3 Clinical Breast Examination (CBE)
    • 7.2.4 Molecular Breast Imaging (MBI)
    • 7.2.5 Breast Ultrasound
  • 7.3 Diagnostic Imaging
    • 7.3.1 X-ray
    • 7.3.2 Magnetic Resonance Imaging (MRI)
    • 7.3.3 Computed Tomography (CT) Scan
    • 7.3.4 Ultrasound
    • 7.3.5 Molecular Imaging Techniques
  • 7.4 Thermography
  • 7.5 Other Applications

8 Global Breast Cancer Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Centers & Medical Laboratories
  • 8.4 Other End Users

9 Global Breast Cancer Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Hologic Inc
  • 11.2 GE Healthcare
  • 11.3 Siemens Healthineers
  • 11.4 Philips Healthcare
  • 11.5 Abbott Laboratories
  • 11.6 Roche Diagnostics
  • 11.7 Thermo Fisher Scientific
  • 11.8 PerkinElmer Inc.
  • 11.9 Agilent Technologies
  • 11.10 Becton, Dickinson and Company (BD)
  • 11.11 Myriad Genetics Inc.
  • 11.12 Sysmex Corporation
  • 11.13 NanoString Technologies
  • 11.14 Genomic Health
  • 11.15 Illumina Inc.
  • 11.16 Bio-Rad Laboratories
  • 11.17 Sienna Cancer Diagnostics
  • 11.18 Cepheid
  • 11.19 Invivo Corporation
  • 11.20 Aurora Diagnostics

List of Tables

  • Table 1 Global Breast Cancer Diagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Breast Cancer Diagnostics Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Breast Cancer Diagnostics Market Outlook, By Instrument-based Products (2023-2034) ($MN)
  • Table 4 Global Breast Cancer Diagnostics Market Outlook, By Platform-based Products (2023-2034) ($MN)
  • Table 5 Global Breast Cancer Diagnostics Market Outlook, By Type (2023-2034) ($MN)
  • Table 6 Global Breast Cancer Diagnostics Market Outlook, By Biopsy (2023-2034) ($MN)
  • Table 7 Global Breast Cancer Diagnostics Market Outlook, By Needle Biopsy (2023-2034) ($MN)
  • Table 8 Global Breast Cancer Diagnostics Market Outlook, By Surgical Biopsy (2023-2034) ($MN)
  • Table 9 Global Breast Cancer Diagnostics Market Outlook, By Imaging (2023-2034) ($MN)
  • Table 10 Global Breast Cancer Diagnostics Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 11 Global Breast Cancer Diagnostics Market Outlook, By Biomarker Testing (2023-2034) ($MN)
  • Table 12 Global Breast Cancer Diagnostics Market Outlook, By Circulating Tumor Cells (CTCs) Testing (2023-2034) ($MN)
  • Table 13 Global Breast Cancer Diagnostics Market Outlook, By Genomic Tests (2023-2034) ($MN)
  • Table 14 Global Breast Cancer Diagnostics Market Outlook, By Gene Expression Profiling (2023-2034) ($MN)
  • Table 15 Global Breast Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 16 Global Breast Cancer Diagnostics Market Outlook, By Nuclear Medicine Diagnostics (2023-2034) ($MN)
  • Table 17 Global Breast Cancer Diagnostics Market Outlook, By Sentinel Lymph Node Biopsy (2023-2034) ($MN)
  • Table 18 Global Breast Cancer Diagnostics Market Outlook, By Positron Emission Tomography (PET) (2023-2034) ($MN)
  • Table 19 Global Breast Cancer Diagnostics Market Outlook, By Histopathology (2023-2034) ($MN)
  • Table 20 Global Breast Cancer Diagnostics Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 21 Global Breast Cancer Diagnostics Market Outlook, By Application (2023-2034) ($MN)
  • Table 22 Global Breast Cancer Diagnostics Market Outlook, By Screening (2023-2034) ($MN)
  • Table 23 Global Breast Cancer Diagnostics Market Outlook, By Mammography (2023-2034) ($MN)
  • Table 24 Global Breast Cancer Diagnostics Market Outlook, By Breast Self-Examination (BSE) (2023-2034) ($MN)
  • Table 25 Global Breast Cancer Diagnostics Market Outlook, By Clinical Breast Examination (CBE) (2023-2034) ($MN)
  • Table 26 Global Breast Cancer Diagnostics Market Outlook, By Molecular Breast Imaging (MBI) (2023-2034) ($MN)
  • Table 27 Global Breast Cancer Diagnostics Market Outlook, By Breast Ultrasound (2023-2034) ($MN)
  • Table 28 Global Breast Cancer Diagnostics Market Outlook, By Diagnostic Imaging (2023-2034) ($MN)
  • Table 29 Global Breast Cancer Diagnostics Market Outlook, By X-ray (2023-2034) ($MN)
  • Table 30 Global Breast Cancer Diagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) (2023-2034) ($MN)
  • Table 31 Global Breast Cancer Diagnostics Market Outlook, By Computed Tomography (CT) Scan (2023-2034) ($MN)
  • Table 32 Global Breast Cancer Diagnostics Market Outlook, By Ultrasound (2023-2034) ($MN)
  • Table 33 Global Breast Cancer Diagnostics Market Outlook, By Molecular Imaging Techniques (2023-2034) ($MN)
  • Table 34 Global Breast Cancer Diagnostics Market Outlook, By Thermography (2023-2034) ($MN)
  • Table 35 Global Breast Cancer Diagnostics Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 36 Global Breast Cancer Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 37 Global Breast Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 38 Global Breast Cancer Diagnostics Market Outlook, By Diagnostic Centers & Medical Laboratories (2023-2034) ($MN)
  • Table 39 Global Breast Cancer Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.